MET amplification assessed using optimized FISH reporting criteria predicts early distant metastasis in patients with non-small cell lung cancer.

about

MET amplification assessed using optimized FISH reporting criteria predicts early distant metastasis in patients with non-small cell lung cancer.

Item

http://www.wikidata.org/entity/Q55347158

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

MET amplification assessed usi ...... th non-small cell lung cancer.

@en

MET amplification assessed usi ...... th non-small cell lung cancer.

@nl

type

Item

label

MET amplification assessed usi ...... th non-small cell lung cancer.

@en

MET amplification assessed usi ...... th non-small cell lung cancer.

@nl

prefLabel

MET amplification assessed usi ...... th non-small cell lung cancer.

@en

MET amplification assessed usi ...... th non-small cell lung cancer.

@nl

P1476

MET amplification assessed usi ...... th non-small cell lung cancer.

@en

P2093

Ching-Hua Liu

http://www.w3.org/2001/XMLSchema#string

David Hong

http://www.w3.org/2001/XMLSchema#string

Hui Chen

http://www.w3.org/2001/XMLSchema#string

Hui Yao

http://www.w3.org/2001/XMLSchema#string

Jin Zhao

http://www.w3.org/2001/XMLSchema#string

L Jeffrey Medeiros

http://www.w3.org/2001/XMLSchema#string

Lianghua Fang

http://www.w3.org/2001/XMLSchema#string

Mark J Routbort

http://www.w3.org/2001/XMLSchema#string

Neda Kalhor

http://www.w3.org/2001/XMLSchema#string

Pei Lin

http://www.w3.org/2001/XMLSchema#string

P2860

Next-Generation Sequencing in Clinical Molecular Diagnostics of Cancer: Advantages and Challenges

Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.

Low EGFR/MET ratio is associated with resistance to EGFR inhibitors in non-small cell lung cancer.

c-Met: structure, functions and potential for therapeutic inhibition

Prognostic value of MET gene copy number and protein expression in patients with surgically resected non-small cell lung cancer: a meta-analysis of published literatures

Functional map and domain structure of MET, the product of the c-met protooncogene and receptor for hepatocyte growth factor/scatter factor

Increased MET Gene Copy Number but Not mRNA Level Predicts Postoperative Recurrence in Patients with Non-Small Cell Lung Cancer

Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer.

Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unit.

Assessment of HER2 Status Using Immunohistochemistry (IHC) and Fluorescence In Situ Hybridization (FISH) Techniques in Mucinous Epithelial Ovarian Cancer: A Comprehensive Comparison between ToGA Biopsy Method and ToGA Surgical Specimen Method.

P304

12959-12970

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.24430

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-02-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29560123

http://www.w3.org/2001/XMLSchema#string

P932

5849187

http://www.w3.org/2001/XMLSchema#string